Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 1998

View Archived Issues

LeukoSite: Q3 1998 highlights

Endorex: Q3 1998 highlights

Synsorb Biotech: Q3 1998 highlights

Celgene: Q3 1998 highlights

MGI Pharma initiates phase II study of MGI-114 in pancreatic cancer patients

CytoTherapeutics receives patent protection for ocular delivery of therapeutic substances

GeneMedicine expands collaboration with Merck for GeneSwitch technology

AVI BioPharma presents advantages of CytoPorter drug delivery engine

Pentose receives SBIR grant to support Inactine development

PEG-Intron A advances to phase III trials for chronic myelogenous leukemia

Positive clinical data supports Siga's unique vaccine delivery system

Tanabe presents water-soluble taxane with better activity than paclitaxel and docetaxel

Nycomed Amersham submits MAA for Diatide's NeoTect to EMEA

New combretastatin A-4 derivative and prodrug profiled at ongoing scientific meeting

Efficacy trial of new prostate cancer treatment initiated at eight leading research centers

Ergo Science receives unapprovable letter from FDA for Ergoset

Unimed returns nitazoxanide rights to Romark

Caution recommended with zidovudine/lamivudine combination: observations of anemia reported

Dopamine D3 receptor antagonists may provide clues about receptor function

Merck & Co. synthesizes potent and orally active p38 inhibitor

Central alpha2-adrenoceptor antagonists claimed by Janssen for depression, Parkinson's disease

Herpesvirus protease inhibitors developed at SmithKline Beecham

AxyS describes new serine protease inhibitors for inflammatory disorders

Lilly's new glutamate receptor antagonists for pain

HIV integrase inhibitors under study at CNRS

FDA and Pfizer revise labeling for Viagra, issue updated information

Antipsychotic drug dropped from Novartis pipeline

First approval for Micardis

Searle revises OPUS-TIMI 16 trial evaluating orbofiban acetate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...